Friday, June 01, 2007
Position Updates: ARWR
7:02AM Arrowhead Research subsidiary, Insert, publishes interim Phase I data from human clinical trials for new cancer drug (ARWR) 7.60 : Co announces that interim Phase I data has been published in the 2007 American Society for Clinical Oncology Proceedings. The abstract's authors state that the stable disease rate, although not yet conclusive, is consistent with promising efficacy. In general, IT-101 was well tolerated and pancytopenia was the dose limiting toxicity. Patients that have completed the six cycle treatment regimen and showed stable disease or better are expected to continue to receive treatment on a compassionate care basis. The first person to enter the trial, a pancreatic cancer patient, is stable after 10 months.
